[
  {
    "ts": null,
    "headline": "Why Amgen (AMGN) Could Be a Hidden Gem Among Dividend Pharma Stocks in 2025",
    "summary": "Amgen Inc. (NASDAQ:AMGN) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. In 2023, the company finalized its $28 billion acquisition of Horizon Therapeutics, a smaller biotech firm. This move helped broaden Amgen’s product portfolio and reduced its reliance on older drugs like Enbrel, which are expected to weigh on future […]",
    "url": "https://finnhub.io/api/news?id=5f3165a4956d0faf08161b234e7aa0d27c735f17d9269bbf02cfc52124d42b5f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752887453,
      "headline": "Why Amgen (AMGN) Could Be a Hidden Gem Among Dividend Pharma Stocks in 2025",
      "id": 136011966,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen Inc. (NASDAQ:AMGN) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. In 2023, the company finalized its $28 billion acquisition of Horizon Therapeutics, a smaller biotech firm. This move helped broaden Amgen’s product portfolio and reduced its reliance on older drugs like Enbrel, which are expected to weigh on future […]",
      "url": "https://finnhub.io/api/news?id=5f3165a4956d0faf08161b234e7aa0d27c735f17d9269bbf02cfc52124d42b5f"
    }
  }
]